(VKTX) Viking Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VKTX) Viking Therapeutics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Viking Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No approved star asset
As of end-2025, Viking Therapeutics is still clinical-stage, with no approved product and no product revenue, so it has no true BCG Star today. Its closest future stars depend on late-stage wins, especially VK2735, which entered Phase 3 obesity testing after strong Phase 2 weight-loss data. Until approval, any share gain is still potential, not real market share.
VK2735 obesity franchise
VK2735 is Viking Therapeutics, Inc.'s lead obesity asset, aimed at a market that Novo Nordisk and Eli Lilly have shown can scale fast. It is still investigational, so current market share is zero, but that also means any clinical win could re-rate the asset sharply. If late-stage data stay strong, VK2735 is Viking Therapeutics, Inc.'s clearest Star candidate.
VK2809 MASH and NASH program
VK2809 is Viking Therapeutics, Inc.'s lead liver-disease asset, and its MASH/NASH focus targets a market with no approved cure and a global adult prevalence often cited near 5% to 6%. That keeps the upside large, but as of 2025 the program is still unapproved, so it is not yet a real Star in BCG terms. Its value depends on late-stage data, FDA success, and proving durable liver-fat and fibrosis benefit.
Oral obesity platform
Viking Therapeutics, Inc.’s oral obesity platform fits the BCG "Stars" box because pills can broaden use beyond injectables, and convenience is a real adoption driver in obesity care.
The global obesity-drug market topped $30 billion in 2024, led by GLP-1 therapies, so even a small share can matter.
Viking still must turn Phase 2 data into sales; its lead oral VK2735 showed up to 14.7% mean weight loss in 13 weeks at 100 mg in 2024.
- Convenience supports uptake
- Market is already large
- Execution risk still matters
Pipeline leadership in metabolic disease
Viking Therapeutics’ strongest value sits in metabolic disease, led by VK2735 in obesity and type 2 diabetes. With obesity affecting more than 1 billion people worldwide and the GLP-1 market still expanding fast, Viking is aimed at a large, high-growth pool, not a mature cash cow. That makes its best assets future Stars if clinical data keep proving out.
- High-growth obesity and diabetes focus
- VK2735 is the key pipeline driver
- Value is tied to future market share
Viking’s Obesity Pipeline Emerges as Its Best BCG Star Bet
Viking Therapeutics, Inc. has no BCG Star yet because it is still clinical-stage and had no product revenue in 2025. Its best Star candidate is VK2735, after Phase 2 obesity data showed up to 14.7% mean weight loss at 13 weeks and it moved into Phase 3. VK2809 also has Star potential, but it is still unapproved and shares zero market share today.
| Asset | 2025 status | Star signal |
|---|---|---|
| VK2735 | Phase 3 | High-growth obesity market |
| VK2809 | Clinical-stage | MASH upside, no approval yet |
What is included in the product
Detailed Word Document
Viking Therapeutics BCG Matrix: one pipeline-focused Question Mark with high growth potential, no Cash Cows, Stars, or Dogs yet.
Editable Excel File
One-page Viking Therapeutics BCG Matrix that quickly spots cash cows, stars, and question marks for faster decisions
Reference Sources
Provides a clear source trail for Viking Therapeutics, Inc. claims, helping investors verify facts fast and make more confident decisions.
Cash Cows
No cash cow product
Viking Therapeutics, Inc. had no marketed product at end-2025, so it had no cash cow to generate steady product revenue. The company still relied on capital markets, with funding driven by equity raises and investment income rather than sales. That means its portfolio is still in the build phase, not the harvest phase.
Zero product revenue
Viking Therapeutics reported zero product revenue in 2025, because it is still a clinical-stage biopharma company with no approved commercial drugs. That means there is no product cash generation to feed the business, so it is the opposite of a Cash Cow in the BCG Matrix. As of year-end 2025, the company still relied on its cash balance and financing, not sales.
No high-share mature franchise
Viking Therapeutics has no cash-cow franchise: in FY2025 it still had no product revenue, and its business was driven by R&D spending, not mature sales. Its lead assets, including VK2735 and VK2809, are still in clinical development, so there is no durable market share in any indication. Cash cows need a leading position in a mature market, and Viking does not have that yet.
No dividend-like cash engine
Viking Therapeutics has no cash cow: in FY2025 it still had no product revenue, so there was no excess cash engine to fund R&D, debt service, or dividends. Its model stayed cash-burn heavy, with spending driven by clinical development rather than steady operating cash inflow.
- No product sales in FY2025
- No dividend-like cash source
- R&D still consumes cash
No low-growth winner
Viking Therapeutics, Inc. has no cash cow in its BCG mix because it still has no approved product and no recurring product revenue. Its lead programs, including VK2735 and VK2809, remain tied to clinical readouts and FDA approval, so they are still question marks or stars, not low-growth cash generators. That means there is no mature, high-share business funding the pipeline.
- No approved product sales.
- Pipeline still needs data.
- No low-growth cash engine.
Viking Therapeutics Has No Cash Cow in FY2025
Viking Therapeutics, Inc. had no Cash Cow in FY2025: product revenue was $0, so there was no mature franchise feeding cash into the business. The company remained clinical-stage, with VK2735 and VK2809 still in development, not commercialization. So the BCG Cash Cow box stays empty.
| FY2025 metric | Value |
|---|---|
| Product revenue | $0 |
| Approved products | 0 |
| Cash cow status | None |
Preview the Actual Deliverable
Viking Therapeutics, Inc. Reference Sources
This Viking Therapeutics, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo content, no hidden changes—just the complete, ready-to-use file. It’s formatted for clear strategic review and immediate practical use. Once purchased, the full version is instantly available to download.
Dogs
VK5211 hip fracture recovery
VK5211 is Viking Therapeutics, Inc.’s older, narrow post-surgical hip fracture recovery program, so it fits the Dog bucket best. Unlike the obesity and liver assets, it addresses a small acute-care setting and has less commercial scale. In Viking Therapeutics, Inc.’s latest reported pipeline, VK5211 remains far behind its lead metabolic programs in strategic value and capital focus.
Phase 2 only
VK5211 is still Phase 2 and has not reached commercialization, so it remains a weak Dogs asset in Viking Therapeutics, Inc.'s BCG Matrix. With no approved sales and limited differentiation, its value as a growth engine is low versus the lead obesity and liver programs. That matters more because Viking Therapeutics, Inc. reported $903.4 million in cash and short-term investments at Q1 2025, so capital is better aimed at higher-probability assets.
Small addressable use case
Recovery after non-elective hip fracture surgery is a niche use case for Viking Therapeutics, Inc., with far smaller demand than obesity or MASH. The U.S. sees about 300,000 hip fractures a year, versus obesity affecting over 100 million adults, so the addressable market is much smaller. That low volume weakens strategic priority and makes this Dogs bucket less attractive in the BCG Matrix.
No product revenue
Viking Therapeutics, Inc.’s VK5211 has no product revenue, so it adds $0 in commercial cash flow while still consuming R&D spend. That fits a Dog in BCG terms: weak market contribution, no sales, and ongoing resource drain. In its latest filing, Viking Therapeutics still showed no approved-product revenue, so the asset remains a cost center rather than a cash generator.
- $0 product revenue
- R&D spend without cash inflow
- Classic Dog profile
Low strategic momentum
Compared with Viking Therapeutics’ lead metabolic programs, VK5211 shows far less strategic momentum and no approved-product revenue. In 2025, Viking still had 0 marketed products, so value creation stayed concentrated in its obesity and NASH pipeline, not this asset. With limited forward movement and a narrow market case, VK5211 fits the Dogs quadrant best.
- 0 marketed products in 2025
- Value focus sits in lead metabolic assets
- VK5211 has limited market pull
VK5211: A Phase 2 Cash Drain With No Revenue
VK5211 is Viking Therapeutics, Inc.’s clearest Dog: Phase 2, no approved sales, and a niche hip-fracture use case. It generated $0 product revenue while Viking Therapeutics, Inc. held $903.4 million in cash and short-term investments at Q1 2025, so capital is better reserved for higher-pull metabolic assets. With 0 marketed products in 2025, VK5211 stays a low-priority cash drain.
| Metric | VK5211 |
|---|---|
| Stage | Phase 2 |
| Product revenue | $0 |
| Cash and short-term investments | $903.4 million |
Question Marks
VK2735 subcutaneous obesity
VK2735 subcutaneous targets obesity, a market that was about 2.9 billion adults worldwide in 2022 and is still growing fast. Its market share is zero today because it is still investigational, but Phase 2 data showed up to 14.7% mean weight loss at 13 weeks, which supports strong future demand if results hold. In Viking Therapeutics, Inc. BCG Matrix terms, it fits a Question Mark now, with a real shot at becoming a Star if late-stage data stay strong.
VK2735 oral obesity
VK2735 oral obesity could improve convenience versus injectables, and that matters because obesity treatment often needs long-term adherence. With about 42% of U.S. adults living with obesity, even small gains in ease of use can widen uptake. It stays a Question Mark because approval, real-world adherence, and commercial adoption are still unproven.
VK2809 MASH and NASH
VK2809 is one of Viking Therapeutics, Inc.’s key pipeline assets, aimed at MASH/NASH, a large unmet-need market tied to obesity and liver disease. With global MASH prevalence estimated at about 5% of adults, the commercial pool is sizable, but VK2809 still needs late-stage data to prove it can move from Question Mark to Star. Its value now depends on clean phase 3 efficacy and safety.
VK0612 type 2 diabetes
VK0612 is a Question Mark in Viking Therapeutics, Inc.'s BCG Matrix: type 2 diabetes affects about 537 million adults worldwide, and the market is crowded with entrenched GLP-1 and insulin players. VK0612 is still in development, so Viking Therapeutics, Inc. has no commercial share yet. That makes it a high-upside but high-risk asset.
- Huge need, intense competition
- No sales yet
- High upside, high risk
VK0214 X-linked adrenoleukodystrophy
VK0214 fits the Question Mark box: X-linked adrenoleukodystrophy is ultra-rare, at about 1 in 17,000 male births, so the unmet need is real, but Viking Therapeutics, Inc. has not yet shown late-stage proof or regulatory traction. Orphan pricing can support returns, yet the asset still carries high clinical and approval risk.
- Rare disease, clear unmet need
- Still unproven in late-stage data
- Needs regulatory progress
- Could move to Star if validated
Viking’s Question Marks: Big Markets, High Risk, Real Upside
Viking Therapeutics, Inc. has several Question Marks: VK2735 subcutaneous and oral, VK2809, VK0612, and VK0214. Each sits in a large or needed market, but none has sales yet, so share is zero and risk is still high. If late-stage data stays strong, the obesity and MASH assets have the best shot at moving toward Star.
| Asset | Market | Signal |
|---|---|---|
| VK2735 SC | 2.9B obese adults | 14.7% loss at 13 weeks |
| VK2809 | ~5% MASH adults | Needs phase 3 proof |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.